Basel, Switzerland (PRWEB) October 21, 2013
The global injectable drug delivery technologies market is estimated to reach $43 billion USD by 2017, much of which is based on drivers like as the surge of biologics and biosimilars and the continuous need to improve patient compliance. Accordingly, the need for a range of innovative delivery devices to accommodate such growth is now more evident than ever and device manufacturers have to further innovate in the key areas of mechanical, industrials and manufacturing designs. To showcase each of these key design areas and connect with our customers in an even more interactive way, SHL will be exhibiting at our Innovation Bar at Booth #64 at PDA’s 2013 - The Universe of Pre-filled Syringes & Injection Devices in Basel, Switzerland from November 5-6th.
SHL’s theme at the 2012 PDA Event was Inspiring Integration, which focused on the importance of integrating services in the areas of development, capabilities and final assembly for drug delivery devices. As a follow up, SHL will be introducing Inspiring Innovation as this year’s PDA theme, more specifically, in the 3 key design areas mentioned above. To further highlight our determination to introduce new innovative ideas to our customers, SHL will have a special “Innovation Bar” by our booth with individual stations to showcase our design expertise. A demonstration station will also be set up where our latest devices will be displayed and demonstrated.
Commenting on this year’s event attendance, Marketing Director Steven Kaufman comments, “This is the first time we’ve exhibited at any conference in this fashion. We hope that through our unique choice of exhibition area, our customers can see that we are a company that is always looking for new innovative ways, whether it’s within our device and manufacturing designs or even just how we present ourselves at conferences. Our goal at this year’s event is to interact with customers by demonstrating not just our devices but highlighting in a more tangible manner how we excel in mechanical, industrial and manufacturing designs. We’ve also been investing heavily in high quality manufacturing equipment for key areas such as molding, tooling, automation and metrology, and expanding our production capacity - we welcome existing customers and potential customers to ask these changes mean for them.”
SHL recently reached a new milestone of 2,000 staff in Taiwan (2,500 globally) as a result of recent expansion and investments in manufacturing capabilities to ensure surplus capacities are always readily available to respond to customer needs in a timely manner.
Look for SHL’s INNOVATION BAR and BOOTH (Booth # 64) at the 2013 PDA Europe beside the entrance to the main conference speaking area.
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices such as auto injectors and pen injectors. We have over 2,500 staff globally, with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia. SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of several distinct group companies:
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
Develops and manufactures equipment solutions for home, hospital and long term care use
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
Provides final assembly, labeling and packaging services of drug delivery devices to the pharmaceutical and biotechnology industries
For additional information visit http://www.shl-group.com or contact us at info(at)shl-group(dot)com
SHL Media Contact
Steven R. Kaufman